Contact

(404) 576-8856

Lab address

2701 N Decatur Rd, Decatur, GA 30033, USA

©2017 by CIS Biotech Inc.

KEY PUBLICATIONS

Publications

  1. Huseynova, Nushaba Panakhova, Pusta Orujova, Safikhan Hasanov, Mehman Guliyev & Agil Orujov. Elevated levels of serum sICAM-1 in asphyxiated low birth weight newborns. Scientific Reports 4, Article number: 6850 (2014) doi:10.1038/srep06850

  2. Klimenko, L.L., Skalny, A.V., Turna, A.A. et al.Serum Trace Element Profiles, Prolactin, and Cortisol in Transient Ischemic Attack Patients.  Biol Trace Elem Res (2016) 172: 93. doi:10.1007/s12011-015-0586-y

  3. Smolko, DG. The level of NMDA-receptor antibodies in patients with chronic cerebrovascular insufficiency. International Neurological Journal 2016. #3 (81) C.66-68. 

  4. González-García Sa, González-Quevedo Aa, Hernandez-Diaz Za, Alvarez Camino Lb, Peña-Sanchez Ma, Cordero-Eiriz Aa, Brown Mc, Gaya JAc, Betancourt-Losa Ma, Fernandez-Almirall Ia, Menendez-Sainz MCa, Fernandez-Carriera Ra. Circulating autoantibodies against the NR2 peptide of the NMDA receptor are associated with subclinical brain damage in hypertensive patients with other pre-existing conditions for vascular risk. J Neurol Sci, 2016, in print

  5. Dambinova SA, Maroon JC, Sufrinko AM, Mullins JD, Alexandrova EV, Potapov AA. Functional, Structural, and Neurotoxicity Biomarkers in Integrative Assessment of Concussions. Front Neurol. 2016 Oct 5;7:172.

  6. Stanca, D. M., Mărginean, I. C., Sorițău, O., Dragoș, C., Mărginean, M., Mureșanu, D. F., Vester, J. C. and Rafila, A, GFAP and antibodies against NMDA receptor subunit NR2 as biomarkers for acute cerebrovascular diseases. J. Cell. Mol. Med., 2015; 19: 2253–2261. doi:10.1111/jcmm.12614   

  7. Kidher E., Patel V.M., Nihoyannopoulos P., et al. Aortic stiffness is related to the ischemic brain injury biomarker N-methyl-D-aspartate receptor antibody levels in aortic valve replacement. Neurol Res Intern. 2014; 2014:970793.

  8. Skitek M., Jerin A. N-methyl-D-aspartate-receptor antibodies, S100 protein, and neuro-specific enolase before and after cardiac surgery: association with ischemic brain injury and epythropoetin prophylaxis. Lab Medicine. 2013; 44(1):56-62. 

  9. Dambinova SA, Bettermann K, Glynn T, Tews M, Olson D, et al. (2012) Diagnostic Potential of the NMDA Receptor Peptide Assay for Acute IschemicStroke. PLoS ONE 7(7): e42362. doi:10.1371/journal.pone.0042362

  10. Weissman J.D., Khunteev G.A., Heath R, Dambinova S.A. NR2 Antibodies: Risk Assessment of Transient Ischemic Attack (TIA)/Stroke in Patients with History of Isolated and Multiple Cerebrovascular Events. J Neurol Sci. 2011; 300(1-2):97-102.

  11. Dambinova S.A. Biomarkers for transient ischemic attack (TIA) and ischemic stroke. Clin Lab Int. 2008; 32(7):7-10.

  12. Bokesch P.M., Izykenova G.A., Justice J.B., Easley K.A., Dambinova S.A.. NMDA receptor antibodies predict adverse neurological outcome after cardiac surgery in high-risk patients. Stroke. 2006;37:1432-1436.

  13. Dambinova S A. “A new brain marker for laboratory assessment of TIA/stroke”, IVD Technol., 2004; 10:43–51.

  14. Dambinova S.A., Khounteev G.A., Izykenova G.A., Zavolokov I.G., Ilyukhina A.Y., Skoromets A.A. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003;49:1752-62.

  15. Dambinova S.A., Khounteev G.A., Skoromets A.A. Multiple panel of biomarkers for TIA/stroke evaluation. Stroke. 2002; 33(5):1181-1182.

  16. Gusev E.I., Skvortsova V.I., Dambinova S.A., et al. Neuroprotective effects of glycine for therapy of acute ischemic stroke. Cerebrovasc Diseases. 2000; 10:49-60.

CIS Biotech, Inc. have signed a license agreement with DRD Biotech for the new Stroke assay

Mar, 2016

CIS Biotech, Inc. have signed a license agreement with DRD Biotech for the new Stroke assay. The new partnership will posses great traction to the market for both companies in area of rapid diagnostics. DRD Biotech developing first ever rapid test for Stroke assessment for ED, hospitals and clinics

Two Lab Tests Help Clinicians Diagnose and Predict Ischemic Stroke

May, 2010

A stroke is one of the most feared medical conditions a person can face. About 2,400 years ago, Hippocrates provided what is most likely the earliest description of what we now term a stroke: a sudden onset of paralysis, which he called apoplexy, a Greek word meaning struck down with violence. About 700,000 strokes occur each year in the United States and account for about $58 billion in direct and indirect costs.

On the mark(ers) Rapid advances seen in diagnostics, risk assessment for cardiovascular disease

Sep 1, 2008

WASHINGTON — Cardiac markers, employed in diagnosis and prognosis for acute coronary syndromes both in central laboratories as well as at the point of care, have represented one of the most rapidly growing segments of the clinical diagnostics market over the past few years. The primary role at present for cardiac markers such as Troponin, creatine kinase-MB (CKMB) and myoglobin is in diagnosis of acute coronary syndromes, but there is growing interest in newer markers that can aid in assessing the risk for myocardial infarction, such as markers of unstable coronary plaque, as well as in stroke markers for initial diagnosis and risk assessment.

New clue for predicting stroke risk: Lp-PLA2

Jul 2, 2008

Acute ischemic stroke tends to trigger “what ifs” and other questions among emergency department staff when ED patients stricken with the condition are left with crippling disabilities: “What if we could have expedited the diagnosis and treatment, or what if the patient had known he or she was high risk and had come in sooner?” And “Could this have been prevented?”

Please reload

News